Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling

The therapeutic landscape of acute myeloid leukemia (AML) has changed with the recent discoveries of novel and targeted therapies. The FDA approval of 8 new AML drugs in a two-year time is unprecedented and is the result of decades of work in leukemia biology and therapeutics. The availability of multiple therapies requires us to develop rational therapy selection strategies to maximize the benefit of therapies and minimize the risk of toxicities for an individual patient. This review will focus on selection of an upfront chemotherapy option for older adults aged ≥60 years with AML, other than acute promyelocytic leukemia.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research